Improved adherence to modern antiretroviral therapy among HIV-infected injecting drug users

HIV Medicine

Volumn 13, Issue 10, 2012, Pages 596-601

  Mann, B ^a   Milloy, M J ^b   Kerr, T ^b,c   Zhang, R ^d   Montaner, J ^b,c   Wood, E ^b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d PROVINCIAL HEALTH SERVICES AUTHORITY   (Canada)

Author keywords

Adherence; Antiretroviral therapy; Injection drug users

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CANADA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 85027928066     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2012.01021.x     Document Type: Article

References (40)

1. Hammer SM, Katzenstein DA, Hughes MD etal. A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter. NEJM 1996; 335: 1081-1090.
2. Hammer SM, Squires KE, Hughes MD etal. A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less. NEJM 1997; 337: 725-733.
3. Wood E, Montaner JSG, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS. Prevalence and Correlates of Untreated Human Immunodeficiency Virus Type 1 Infection among Persons Who Have Died in the Era of Modern Antiretroviral Therapy. J Infect Dis 2003; 188: 1164-1170.
4. Bruce RD, Altice FL. Clinical care of the HIV-infected drug user. Infect Dis Clin North Am 2007; 21: 149-179.
5. Karon JM, Fleming PL, Steketee RW, De Cock KM. HIV in the United States at the turn of the Century: an epidemic in transition. Am J Public Health 2001; 91: 1060-1068.
6. Mathers B, Degenhardt L, Phillips B etal. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372: 1733-1745.
7. Paterson DL, Sindells S, Mohr J etal. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection. Ann Intern Med 2000; 133: 21-30.
8. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003; 362: 2002-2011.
9. Stein MD, Rich JD, Maksad J etal. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse 2000; 26: 195-205.
10. Kerr T, Palepu A, Barness G etal. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. AVT 2004; 9: 407-414.
11. Liu H, Longshore D, Williams JK etal. Substance abuse and medication adherence among HIV-positive women with histories of child sexual abuse. AIDS Behav 2006; 10: 279-286.
12. Arnsten JH, Li X, Mizuno Y etal. Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. JAIDS 2007; 46 (Suppl. 2): S64-S71.
13. Carrieri MP, Chesney MA, Spire B etal. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. IJBM 2003; 10: 1-14.
14. Gordillo V, del Amo J. Soriano V and Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999; 13: 1763-1769.
15. Palepu A, Tyndall MW, Joy R etal. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend 2006; 84: 188-194.
16. Strathdee SA, Palepu A, Cornelisse PGA etal. Barriers to Use of Free Antiretroviral Therapy in Injection Drug Users. JAMA 1998; 280: 547-549.
17. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JSG. Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350×10[9] cells/L. Ann Intern Med 2003; 139: 810-816.
18. Wood E, Hogg RS, Lima VD etal. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 2008; 300: 550-554.
19. Hogg RS, Heath K, Bangsberg D etal. Intermittent use of triple combination therapy is predictive of mortality at baseline and after one year of follow-up. AIDS 2002; 16: 1051-1058.
20. d'ArminioMonforte A, Lepri AC, Rezza G etal. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14: 499-507.
21. Wood E, Montaner JSG, Yip B etal. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 2003; 169: 656-661.
22. Palepu A, Yip B, Miller C etal. Factors associated with the response to antiretroviral therapy among HIV-infected patietns with and without a history of injection drug use. AIDS 2001; 15: 423-424.
23. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. JAIDS 2000; 23: 360-361.
24. Hogg RS, Heath K, Bangsberg D etal. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16: 1051-1058.
25. WHO. World Health Organization, Child and Adolescent Health. Regional Office for South-East Asia, WHO, 2011.
26. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350×10(9) cells/L. Ann Intern Med 2003; 139: 810-816.
27. Maldonado G, Grenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138: 923-936.
28. Lima V, Fernandes K, Rachlis B, Druyts E, Montaner J, Hogg R. Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patients. Soc Sci Med 2009; 68: 1044-1049.
29. Milloy M-J, Kerr T, Buxton J etal. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis 2011; 203: 1215-1221.
30. Bouhnik A-D, Chesney M, Carrieri P etal. Nonadherence among HIV-infected injecting drug users: the impact of social instability. JAIDS 2002; 31: S149-153.
31. Celentano DD, Vlahov D, Cohn S, Shadle VM, Olugbenga O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998; 280: 544-546.
32. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 2000: S171-S1S6.
33. Ortego C, Huedo-Medina T, Llorca J etal. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav 2011; 15: 1381-1396.
34. Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav 2010; 14: 731-747.
35. Nachega JB, Mugavero MJ, Zeier M, Vitoria M, Gallant JE. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence 2011; 5: 357-367.
36. Atkinson MJ, Petrozzino JJ. An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. AIDS Patient Care STDS 2009; 23: 903-914.
37. Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ. Better maintained adherence on switchign from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005; 6: 185-190.
38. Krusi A, Milloy M-J, Kerr T etal. Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting. Antivir Ther 2010; 15: 789-796.
39. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JSG. Adherence to triple therapy and viral load response. JAIDS 2000; 23: 360-361.
40. Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction 2008; 103: 1242-1257.